Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays

Helicobacter

Volumn 22, Issue 4, 2017, Pages

  Leja, Marcis ^a,b,c   Camargo, M Constanza ^d   Polaka, Inese ^a,e   Isajevs, Sergejs ^a,b,f   Liepniece Karele, Inta ^a,b,f   Janciauskas, Dainius ^g   Rudzite, Dace ^a,b   Kikuste, Ilze ^a,c   Vanags, Aigars ^c   Kojalo, Ilona ^a,b   Folkmanis, Valdis ^a   Kirsners, Arnis ^a,b,e   Tolmanis, Ivars ^c   Rabkin, Charles S ^d  

^a UNIVERSITY OF LATVIA   (Latvia)

^b RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^c Digestive Diseases Centre GASTRO   (Latvia)

^d NATIONAL CANCER INSTITUTE   (United States)

^e RIGA TECHNICAL UNIVERSITY   (Latvia)

^f Academic Histology Laboratory   (Latvia)

^g Lithuanian Agriculture University   (Lithuania)

Author keywords

atrophy; gastric cancer; pepsinogen; risk stratification; stomach

Indexed keywords

PEPSINOGEN I; PEPSINOGEN II; PEPSINOGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LATEX AGGLUTINATION TEST; LATEX AGGLUTINATION TEST KIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STOMACH ATROPHY; UNIVERSITY HOSPITAL; VERY ELDERLY; ADOLESCENT; ATROPHY; BLOOD; COMPARATIVE STUDY; CYTOCHEMISTRY; DIAGNOSTIC TEST; EVALUATION STUDY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; STOMACH DISEASE; STOMACH MUCOSA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATROPHY; DIAGNOSTIC TESTS, ROUTINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC MUCOSA; HISTOCYTOCHEMISTRY; HUMANS; LATEX FIXATION TESTS; MALE; MIDDLE AGED; PEPSINOGENS; ROC CURVE; STOMACH DISEASES; YOUNG ADULT;

EID: 85019729008     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12393     Document Type: Article

References (25)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr, accessed on 03/12/2016. 2013.
2. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30.
3. Fock KM, Katelaris P, Sugano K, et al. Second asia-pacific consensus guidelines for helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587-1600.
4. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141-147.
5. Samloff IM. Pepsinogens, pepsins, and pepsin inhibitors. Gastroenterology. 1971;60:586-604.
6. Agreus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012;47:136-147.
7. Di Mario F, Cavallaro LG, Moussa AM, et al. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci. 2006;51:1791-1795.
8. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J Gastroenterol. 2005;40:938-944.
9. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245-253.
10. Miki K, Fujishiro M. Cautious comparison between East and West is necessary in terms of the serum pepsinogen test. Dig Endosc. 2009;21:134-135.
11. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
12. Quinlan JR. C4.5: Programs for Machine Learning. Morgan Kaufmann Publishers Inc, 1993. Mach Learn. 1994;16:235-240.
13. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA Data Mining Software: an Update. SIGKDD Explor Newsl. 2009;11:10-18.
14. Samloff IM, Liebman WM. Radioimmunoassay of group I pepsinogens in serum. Gastroenterology. 1974;66:494-502.
15. Nomura AM, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med. 1980;93:537-540.
16. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - “ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:405-414.
17. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastro Hepatol. 2012;24:37-41.
18. Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0142080.
19. Brenner H, Rothenbacher D, Weck MN. Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value. Int J Cancer. 2007;121:2782-2786.
20. Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS ONE. 2014;9:e109783.
21. Kim N, Jung HC. The role of serum pepsinogen in the detection of gastric cancer. Gut Liv. 2010;4:307-319.
22. Huang Z, Zhang X, Lu H, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC Gastroenterol. 2014;14:74.
23. Checchi S, Montanaro A, Pasqui L, et al. Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodies. J Clin Endocrinol Metab. 2007;92:4346-4351.
24. Bornschein J, Leja M, Kupcinskas J, et al. Molecular diagnostics in gastric cancer. Front Biosci. 2014;19:312-338.
25. Zayakin P, Ancans G, Silina K, et al. Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 2013;132:137-147.